A new U.S. tariff framework for pharmaceuticals could affect how pharmacies and other healthcare stakeholders think about drug sourcing, pricing, and access. On April 2, 2026, the White House issued a proclamation imposing new tariffs on certain imported patented pharmaceuticals and pharmaceutical ingredients, with implementation beginning July 31, 2026 for companies listed in Annex III and September 29, 2026, for other affected companies. The administration explicitly excluded generic pharmaceuticals and their associated ingredients from Section 232 tariffs “at this time.”

That distinction matters, because it suggests near-term exposure may be more concentrated in branded products than in the generic drugs that make up most prescription volume. This is not a blanket tariff on all drugs. The policy is aimed primarily at patented, branded products. It also uses tariff relief to encourage two manufacturer commitments: (1) more U.S.-based production and research activity, and (2) Most-Favored-Nation (MFN) pricing arrangements with the federal government. The new framework ties lower tariff treatment directly to those commitments.

Not a Single Tariff, but a Tiered Framework

The new policy creates several different tariff pathways.

• Certain patented pharmaceuticals and related ingredients can face a 100% tariff if they are not protected by a qualifying agreement.
• Companies with approved or in-principle onshoring plans may qualify for a 20% rate, which the proclamation says would rise to 100% on April 2, 2030, if conditions are not met.
• Products of the European Union, Japan, South Korea, Switzerland, and Liechtenstein are subject to a 15% rate unless a lower company-specific rate applies.
• Products of the United Kingdom start at 10% and can fall to zero if a U.S.-UK pharmaceutical pricing agreement requires it.
• The proclamation also provides zero-tariff treatment for certain orphan drugs and other specialty categories.

Where more than one tariff category could apply, the lowest applicable rate governs.

Tariffs Are Also Being Used as a Pricing Tool

The tariff framework is not just a trade policy. It is also being used as a pricing lever. Reuters reported that large drugmakers have been offered tariff relief in exchange for lower U.S. prices, MFN commitments, participation in direct-to-patient channels such as TrumpRx.gov, and additional U.S. investment. Reuters also reported that 16 major pharmaceutical companies had publicly announced such agreements as of April 2, while others like Regeneron said they expected to finalize deals soon and avoid the new tariffs.

 

What Pharmacies Should and Should Not Assume

The proclamation does not automatically reset published benchmark drug prices or guarantee immediate price changes at the pharmacy counter. It imposes import duties on certain products; it does not, by itself, order a change to WAC, AWP, or a specific reimbursement benchmark. Any downstream price effect depends on how manufacturers, PBMs, wholesalers, and payers respond. This is an inference from the tariff structure and current public reporting, not an explicit promise in the proclamation itself.

Reuters noted that generic drugs remain exempt and identified that more than 90% of medicines sold in the United States are generics. Combined with the delayed effective dates and the possibility of additional company agreements before implementation, immediate system-wide pharmacy impact may be limited.

That said, exposure is still real, especially for higher-cost branded therapies and products with limited substitution options. If tariffs ultimately apply to specific patented products, manufacturers may respond in several ways: absorb some of the cost, adjust future pricing strategies, renegotiate rebates or channel contracts, shift sourcing, or revisit where products are manufactured. Pharmacies may feel pressure first through acquisition cost changes, gross-to-net shifts, or supply dynamics, rather than through an obvious list-price change on day one. This is a forward-looking inference, but it is consistent with how tariff costs typically move through the supply chain.

Where Pharmacy Organizations May Want to Focus

For pharmacies and other stakeholders, the most practical next step is not to speculate broadly, but to identify where exposure is concentrated. A recent memo to National Association of Chain Drug Store (NACDS) members recommended reviewing high-volume branded products, confirming whether those products are patented, identifying manufacturers’ tariff status, and determining countries of origin where possible. Tariff exposure is likely to be concentrated in a narrower slice of branded products rather than spread evenly across the market.

This may also increase the strategic importance of manufacturer outreach. For affected branded drugs, pharmacies and other stakeholders may need more product-specific clarity around sourcing, tariff treatment, and whether the manufacturer expects an exemption, a reduced rate, or full exposure.

Conclusion

The April 2026 pharmaceutical tariff policy is best understood as a targeted pressure mechanism, not a blanket tax on all drugs. Generics are currently exempt; patented products face tiered treatment, and tariff relief is being used to drive both domestic manufacturing and lower-price commitments. For pharmacies, the immediate question is not whether every published drug price will rise, but which branded products, manufacturers, and sourcing channels carry meaningful exposure and how those costs eventually materialize.

The policy may evolve further before the first tariffs take effect. For now, the most important step is to monitor high-cost branded exposure, confirm manufacturer tariff status where possible, and stay close to supply chain and contracting partners as the policy develops.